Morgan Stanley analyst Tejas Savant lowered the firm’s price target on Myriad Genetics (MYGN) to $7 from $16 and keeps an Equal Weight rating on the shares. A “disappointing” Q1 miss was driven by softness in GeneSight and hereditary cancer tests in the unaffected population, says the analyst, who adds that while the pipeline “holds promise,” it “remains a show-me story at this time.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics price target lowered to $9 from $12.50 at Piper Sandler
- Hold Rating Maintained for Myriad Genetics Amid Revenue Cuts and Strategic Uncertainty
- Myriad Genetics Faces Challenges Amid Prenatal Testing Growth
- Myriad Genetics downgraded to Peer Perform from Outperform at Wolfe Research
- China announces stimulus measures, Disney reports Q2 beat: Morning Buzz